DE60045114D1 - Zubereitungen zur Erhöhung der Bioverfügbarkeit von oral verabreichten pharmazeutischen Verbindungen - Google Patents

Zubereitungen zur Erhöhung der Bioverfügbarkeit von oral verabreichten pharmazeutischen Verbindungen

Info

Publication number
DE60045114D1
DE60045114D1 DE60045114T DE60045114T DE60045114D1 DE 60045114 D1 DE60045114 D1 DE 60045114D1 DE 60045114 T DE60045114 T DE 60045114T DE 60045114 T DE60045114 T DE 60045114T DE 60045114 D1 DE60045114 D1 DE 60045114D1
Authority
DE
Germany
Prior art keywords
orally administered
increasing
bioavailability
preparations
pharmaceutical compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60045114T
Other languages
English (en)
Inventor
Johannes Henricus Matthias Schellens
Alfred Hermanus Schinkel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cancer Research Ventures Ltd
Original Assignee
Cancer Research Ventures Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cancer Research Ventures Ltd filed Critical Cancer Research Ventures Ltd
Application granted granted Critical
Publication of DE60045114D1 publication Critical patent/DE60045114D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE60045114T 1999-05-17 2000-05-17 Zubereitungen zur Erhöhung der Bioverfügbarkeit von oral verabreichten pharmazeutischen Verbindungen Expired - Lifetime DE60045114D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NL1012066 1999-05-17
NL1012481 1999-06-30

Publications (1)

Publication Number Publication Date
DE60045114D1 true DE60045114D1 (de) 2010-11-25

Family

ID=26642978

Family Applications (2)

Application Number Title Priority Date Filing Date
DE60045114T Expired - Lifetime DE60045114D1 (de) 1999-05-17 2000-05-17 Zubereitungen zur Erhöhung der Bioverfügbarkeit von oral verabreichten pharmazeutischen Verbindungen
DE60030283T Expired - Lifetime DE60030283T2 (de) 1999-05-17 2000-05-17 Zusammensetzungen zur erhöhung der bioverfügbarkeit von oral verabreichten pharmazeutischen verbindungen

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE60030283T Expired - Lifetime DE60030283T2 (de) 1999-05-17 2000-05-17 Zusammensetzungen zur erhöhung der bioverfügbarkeit von oral verabreichten pharmazeutischen verbindungen

Country Status (10)

Country Link
US (2) US7030132B2 (de)
EP (2) EP1749540B1 (de)
AT (2) ATE337016T1 (de)
AU (1) AU4955200A (de)
CY (1) CY1105795T1 (de)
DE (2) DE60045114D1 (de)
DK (1) DK1189637T3 (de)
ES (1) ES2270834T3 (de)
PT (1) PT1189637E (de)
WO (1) WO2000069390A2 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9718903D0 (en) * 1997-09-05 1997-11-12 Glaxo Group Ltd Method,compositions and kits for increasing the oral bioavailability of pharmaceutical agents
DK1189637T3 (da) * 1999-05-17 2006-12-11 Cancer Res Ventures Ltd Produkter til forbedring af biotilgængeligheden for oralt indgivne medikamenter
HU0100947D0 (en) * 2001-03-02 2001-05-28 Solvo Kft Screening system based on expression of abcg2 half transporter protein in an expression system free of other abc-transporters, abcg2 homodimers
US7169763B2 (en) * 2002-02-22 2007-01-30 Oliver Yoa-Pu Hu Cytochrome P450 3A inhibitors and enhancers
US20080312250A1 (en) * 2004-07-01 2008-12-18 The Netherlands Cancer Institute Combination Comprising a Bcrp Inhibitor and 4- (4-Methylpiperazin-1-Ylmethyl)-N-[4-Methyl-3- (4-Pyridin-3-Yl) Pyrimidin-2-Ylamino) Phenyl] -Benzamide
CN101010114B (zh) 2004-08-27 2010-05-26 皇家飞利浦电子股份有限公司 电子遥控药丸和用于供应至少一种药物的系统
WO2006056944A1 (en) * 2004-11-29 2006-06-01 Koninklijke Philips Electronics N.V. Electronically controlled pill
WO2006065125A1 (en) * 2004-12-16 2006-06-22 Het Nederlands Kanter Instituut Means and methods for determining and/or influencing transportation
WO2009083042A1 (en) * 2007-12-31 2009-07-09 Olaf Van Tellingen Methods and means for the treatment of cancer
US20100331827A1 (en) * 2008-02-18 2010-12-30 Koninklijke Philips Electronics N.V. Administration of drugs to a patient
CN101983029B (zh) * 2008-03-31 2015-01-14 皇家飞利浦电子股份有限公司 制备包括传感器的可吞服胶囊的方法
KR101367219B1 (ko) 2008-04-30 2014-03-14 지멘스 메디컬 솔루션즈 유에스에이, 인크. 기질 기재 ｐｅｔ 조영제
JP5500600B2 (ja) * 2008-06-19 2014-05-21 コーニンクレッカ フィリップス エヌ ヴェ 湿った環境における粉状薬物の供給のためのデバイス
RU2011102576A (ru) * 2008-06-25 2012-07-27 Конинклейке Филипс Электроникс Н.В. (Nl) Электронная таблетка, содержащая множество емкостей с лекарственным средствами
US10046109B2 (en) 2009-08-12 2018-08-14 Progenity, Inc. Drug delivery device with compressible drug reservoir
CN106432490B (zh) * 2016-09-14 2020-01-07 北京大学 一种abcg2单克隆抗体及其用途

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ201084A (en) 1982-06-25 1985-10-11 New Zealand Dev Finance 4-carboxamidoacridine derivatives and pharmaceutical compositions containing such
KR100220538B1 (ko) * 1991-01-11 1999-09-15 뮈쉘 쥐르밀 아크리딘 유도체
WO1994001408A1 (en) 1992-07-10 1994-01-20 Laboratoires Glaxo S.A. Anilide derivatives
US5567592A (en) 1994-02-02 1996-10-22 Regents Of The University Of California Screening method for the identification of bioenhancers through the inhibition of P-glycoprotein transport in the gut of a mammal
US5786344A (en) 1994-07-05 1998-07-28 Arch Development Corporation Camptothecin drug combinations and methods with reduced side effects
NZ295546A (en) 1994-10-05 1999-01-28 Glaxo Wellcome Inc Parenteral medicament containing n-{4-[2-1,2,3,4-tetrahydro-6,7-dimethoxy-2-isoquinolinyl)-ethyl]-phenyl}- 9,10-dihydro-5-methoxy-9-oxo-4-acridine carboxamide, surfactant, and buffer
US5726181A (en) 1995-06-05 1998-03-10 Bionumerik Pharmaceuticals, Inc. Formulations and compositions of poorly water soluble camptothecin derivatives
US6245805B1 (en) 1995-10-26 2001-06-12 Baker Norton Pharmaceuticals, Inc. Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents
GB9710612D0 (en) 1997-05-23 1997-07-16 Glaxo Group Ltd Synthesis of acridine derivatives
DE69832173T2 (de) 1997-05-27 2006-08-03 IVAX RESEARCH, INC., Miami Zusammensetzungen zur oralen verabreichung von taxanen und deren verwendung
GB9718903D0 (en) 1997-09-05 1997-11-12 Glaxo Group Ltd Method,compositions and kits for increasing the oral bioavailability of pharmaceutical agents
WO1999040110A1 (en) * 1998-02-05 1999-08-12 University Of Maryland, Baltimore Breast cancer resistance protein (bcrp) and the dna which encodes it
JP2002518332A (ja) 1998-06-18 2002-06-25 ジョージワシントン大学 副作用低減を伴う癌治療のためのカンプトテシン化合物の投与方法
JP2002522392A (ja) 1998-08-05 2002-07-23 アベンテイス・フアルマ・ソシエテ・アノニム 低下された消化管毒性を有するカンプトテシン誘導体の使用
DK1189637T3 (da) * 1999-05-17 2006-12-11 Cancer Res Ventures Ltd Produkter til forbedring af biotilgængeligheden for oralt indgivne medikamenter
US6521635B1 (en) 2000-01-20 2003-02-18 The United States Of America As Represented By The Department Of Health And Human Services Inhibition of MXR transport by acridine derivatives

Also Published As

Publication number Publication date
ATE484295T1 (de) 2010-10-15
AU4955200A (en) 2000-12-05
WO2000069390A2 (en) 2000-11-23
US20020128282A1 (en) 2002-09-12
EP1749540A3 (de) 2007-05-30
US7030132B2 (en) 2006-04-18
DE60030283T2 (de) 2007-09-20
WO2000069390A3 (en) 2001-12-13
ATE337016T1 (de) 2006-09-15
ES2270834T3 (es) 2007-04-16
CY1105795T1 (el) 2011-02-02
EP1749540A2 (de) 2007-02-07
EP1749540B1 (de) 2010-10-13
EP1189637A2 (de) 2002-03-27
DK1189637T3 (da) 2006-12-11
US20060128743A1 (en) 2006-06-15
EP1189637B1 (de) 2006-08-23
PT1189637E (pt) 2007-01-31
DE60030283D1 (de) 2006-10-05

Similar Documents

Publication Publication Date Title
DE60045114D1 (de) Zubereitungen zur Erhöhung der Bioverfügbarkeit von oral verabreichten pharmazeutischen Verbindungen
ATE339954T1 (de) Kombinationen von formoterol und tiotropium-salz
CY1121133T1 (el) Τοπικα εφαρμοσιμο φαρμακευτικο παρασκευασμα
NZ324801A (en) Oral pharmaceutical dosage form containing taxol or etoposide derivatives and a bioenhancer compound
DE69526428D1 (de) Verfahren zur erhöhung der bioverfügbarkeit oraler arzneimittel
CA2301017A1 (en) Use of propyl gallate to increase bioavailability of orally administered pharmaceutical compounds
CY1112562T1 (el) Φαρμακευτικες συνθεσεις για τη στοματικη χορηγηση της καλσιτονινης
BR9912694A (pt) Composto para preparar medicamento de administração pulmonar
EA200401019A1 (ru) Дозированная лекарственная форма для перорального применения, содержащая ингибитор pde 4 в качестве действующего вещества и поливинилпирролидон в качестве вспомогательного вещества
ATE514424T1 (de) Pharmazeutische zubereitungen von taxanen
CY1107675T1 (el) Φαρμακευτικα αλατα τραμαδολης
ES2110377T1 (es) Formulacion galenica de fenofibrato y aplicacion de la misma.
ATE292453T1 (de) Antivirale arznei
SE8100276L (sv) Farmaceutiskt aktiv komposition omfattande ketoner och heterocykliska foreningar
EE200300371A (et) Peroraalselt ja paikselt manustatavad farmatseutilised kopmositsioonid
DK1152763T3 (da) Anvendelse af desozypeganin til behandling af stofafhængighed
SE9902742D0 (sv) New pharmaceutical formultion